Abstract: S100A8-inhibiting peptides include (A) a peptide of 5 to 10 residues in length containing a fifth alanine (Ala) from an N-terminus in an amino acid sequence of SEQ ID NO: 1, or (B) a peptide consisting of an amino acid sequence of SEQ ID NO: 2.

Abstract: A screening method directed towards; (1) specifying a receptor binding site by introduction of mutation, and (2) specifying a binding site-specific peptide motif on the basis of an amino acid selection ratio by contrast between a peptide motif bound to a wild-type subunit and a peptide motif bound to a mutant functionally deficient in the binding site according to a peptide library method. A peptide which inhibits a toxin whose receptor binding portion has a subunit structure is screened. Accordingly, an STX2 inhibitor in which an STX2 inhibiting peptide is incorporated in a molecular nuclear structure portion having three molecules of lysine (Lys) peptide-linked thereto and which is easy to synthesize and can inhibit verotoxin is provided.

Abstract: A screening method comprises the following steps; (1) specifying a receptor binding site by introduction of mutation, and (2) specifying a binding site-specific peptide motif on the basis of an amino acid selection ratio by contrast between a peptide motif bound to a wild-type subunit and a peptide motif bound to a mutant functionally deficient in the binding site according to a peptide library method. A peptide which inhibits a toxin whose receptor binding portion has a subunit structure is screened. Accordingly, an STX2 inhibitor in which an STX2 inhibiting peptide is incorporated in a molecular nuclear structure portion having three molecules of lysine (Lys) peptide-linked thereto and which is easy to synthesize and can inhibit verotoxin is provided.

Abstract: A carbosilane dendrimer compound containing sugar chain in its chemical structure that show neutralizing activity against verotoxin and antiviral activity, and a process for producing the same are provided. Further, a carbosilane dendrimer compound that contains sialyllactose at its terminus, which can specifically bind and adhered to viruses, is provided.

Abstract: The invention provides methods for rapidly determining kinase binding site motifs using a oriented degenerate peptide library approach. The methods involve the selection of peptides by binding affinity. Inhibitors of kinases that include or compete for the binding site motifs determined using the methods also are provided, as are methods and compositions for using these binding site motifs and inhibitors.